Related references
Note: Only part of the references are listed.Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT-derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
Erwin Woff et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib
Yoojoo Lim et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
Nicolas Aide et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
Erwin Woff et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
Jung Han Kim
ONCOTARGET (2016)
PET Scans as a Predictive Marker of Survival in Advanced Colorectal Cancer
Minsig Choi et al.
CLINICAL COLORECTAL CANCER (2015)
Biomarker: Predictive or Prognostic?
Karla V. Ballman
JOURNAL OF CLINICAL ONCOLOGY (2015)
First-line chemotherapy for mCRC-a review and evidence-based algorithm
Chiara Cremolini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
Alain Hendlisz et al.
BMJ OPEN (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).
Am Lie Deleporte et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab
Kristin Skougaard et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
Geraldine Gebhart et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A. Hendlisz et al.
ANNALS OF ONCOLOGY (2012)
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
P. Bystrom et al.
ANNALS OF ONCOLOGY (2009)
Monitoring and Predicting Response to Therapy with F-18-FDG PET in Colorectal Cancer: A Systematic Review
Lioe-Fee de Geus-Oei et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Share Paper
